Advanced search
Publication Cover
Current Medical Research and Opinion Volume 37, 2021 - Issue 1
Submit an article Journal homepage
196
Views
0
CrossRef citations to date
0
Altmetric
Cardiovascular

Hierarchical modeling of blood pressure determinants and outcomes following valsartan treatment in hypertensive patients with known comorbidities: pooled analysis of six prospective real-world studies including 11,999 patients

Nimer Alkhatiba Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, Tucson, AZ, USA;b College of Pharmacy, Al-Zaytoona University of Jordan, Amman, JordanORCID Iconhttps://orcid.org/0000-0001-5071-9257
ORCID Icon,
Diana Suna Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, Tucson, AZ, USA
,
Kris Denhaerynckc Institute of Nursing Science and Department of Public Health, University of Basel, Basel, Switzerland;d Matrix45, Tucson, AZ, USA
,
Dina Hamarneha Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, Tucson, AZ, USA
,
Yoleen Van Campa Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, Tucson, AZ, USA;e Centre for Research and Innovation in Care, University of Antwerp, Antwerp, Belgium
,
Lorenzo Villaa Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, Tucson, AZ, USA;f Department of Epidemiology and Biostatistics, College of Public Health, University of Arizona, Tucson, AZ, USA
,
Heidi Briég Novartis Pharma, Vilvoorde, Belgium
,
Stefaan Vancayzeeleg Novartis Pharma, Vilvoorde, Belgium
,
Karen MacDonaldc Institute of Nursing Science and Department of Public Health, University of Basel, Basel, SwitzerlandORCID Iconhttps://orcid.org/0000-0002-4568-9783
ORCID Icon &
Ivo Abrahama Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, Tucson, AZ, USA;h Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ, USA;i Department of Family and Community Medicine, College of Medicine – Tucson, University of Arizona, Tucson, AZ, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-0490-4421
ORCID Icon show all
Pages 1-8 | Received 13 Aug 2020, Accepted 16 Nov 2020, Published online: 11 Dec 2020

References

  • Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018;138:e426–e483.
  • Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–3104.
  • Okonofua EC, Simpson KN, Jesri A, et al. Therapeutic inertia is an impediment to achieving the healthy people 2010 blood pressure control goals. Hypertension. 2006;47(3):345–351.
  • Van Wijk BLG, Klungel OH, Heerdink ER, et al. Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertension. 2005;23:2101–2107.
  • der Niepen V, Woestenburg A, Brié H, et al. Effectiveness of valsartan for treatment of hypertension: patient profiling and hierarchical modeling of determinants and outcomes (the PREVIEW study. Ann Pharmacother. 2009;43(5):849–861.
  • European Society of Hypertension – European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertension. 2003;21:101–1053.
  • Van der Niepen P, Brie H, Vancayzeele S, et al. Effectiveness of valsartan for the treatment of hypertension: hierarchical linear and logistic modeling of determinants and outcomes (the Belgian IMPROVE study). Poster presented at the 2009 meeting of the Belgian Association of Pharmaceutical Physicians, Brussel, Belgium.
  • Lins R, Coen N, Aerts A, et al. Effectiveness of valsartan 160/HCTZ25 for treatment of hypertension in difficult-to-treat or treatment-resistant patients: hierarchical linear and logistic modeling of determinants and outcomes (the Belgian INSIST study). Poster presented at the 2009 meeting of the Belgian Association of Pharmaceutical Physicians, Brussel, Belgium. 2009.
  • Lins R, Coen N, Aerts A, et al. Modelling of blood pressure and total cardiovascular risk outcomes after second-line valsartan therapy: the BSCORE study. Arch Cardiovasc Dis. 2011;104(8–9):428–434.
  • Lins R, Aerts A, Coen N, et al. Effectiveness of amlodipine-valsartan single-pill combinations: hierarchical modeling of blood pressure and total cardiovascular disease risk outcomes (the EXCELLENT study). Ann Pharmacother. 2011;45(6):727–739.
  • Abraham I, MacDonald K, Hermans C, et al. Real-world effectiveness of valsartan on hypertension and total cardiovascular risk: review and implications of a translational research program. Vasc Health Risk Manag. 2011;7:209–235.
  • Choudhry NK, Fletcher RH, Soumerai SB. The relationship between clinical experience and quality of health care. Ann Intern Med. 2005;142(4):260–273.
  • Phillips L, Branch W, Cook C, et al. Clinical inertia. Ann Intern Med. 2001;135(9):825–834.
  • Redon J, Coca A, Lazaro P, et al. Factors associated with therapeutic inertia in hypertension: validation of a predictive model. J Hypertension. 2010;28:1770–1777.
  • Chen Q, Zhang X, Gu J, et al. General practitioners’ hypertension knowledge and training needs: a survey in Xuhui district, Shanghai. BMC Fam Pract. 2013;14(1):16.
  • Ekesbo R, Midlov P, Gerward S, et al. Lack of adherence to hypertension treatment guidelines among GPs in southern Sweden – a case report-based survey. BMC Fam Pract. 2012;13:34.
  • Cabana M, Rand C, Powe N, et al. Why don’t physicians follow clinical practice guidelines? A framework for improvement. JAMA. 1999;282(15):1458–1465.
  • Villa L, Sun D, Denhaerynck K, et al. Predicting blood pressure outcomes using single-item physician-administered measures: a retrospective pooled analysis of observational studies in Belgium. Br J Gen Pract. 2015;65(630):e9–e15.
  • Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326(7404):1427.
  • Bramlage P, Bohm M, Volpe M, et al. A global perspective on blood pressure treatment and control in a referred cohort of hypertensive patients. J Clin Hypertens. 2010;12(9):666–677.
  • Fagard RH, Van Den Enden M, Leeman M, et al. Survey on treatment of hypertension and implementation of World Health Organization/International Society of Hypertension risk stratification in primary care in Belgium. J Hypertension. 2002;20:1297–1302.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.